PT-141

Most Common Uses

PT-141 is primarily used to address sexual dysfunction. It functions as a melanocortin receptor agonist, stimulating pathways in the brain associated with sexual arousal and desire. The peptide is approved for treating hypoactive sexual desire disorder (HSDD) in premenopausal women, offering a targeted approach to improve sexual interest and satisfaction. Additionally, PT-141 is explored for its potential in managing erectile dysfunction in men, showing promise in enhancing sexual performance through non-vascular mechanisms. Unlike traditional treatments, it acts directly on the central nervous system, making it a unique option for people unresponsive to other therapies. Research also suggests possible applications in addressing other conditions related to melanocortin pathways, though these remain under investigation.

History of PT-141

Back in the early 1960s, researchers noticed that giving rats a hormone called α-MSH triggered sexual arousal. This discovery sparked interest in α-MSH’s potential effects on humans. In the 1980s, a team at the University of Arizona began experimenting with α-MSH and similar molecules to create a sunless tanning compound. From these efforts, they synthesized two new peptides—melanotan I and melanotan II.

One of the researchers, Mac Hadley, famously tested melanotan II on himself, accidentally injecting double the intended amount. The result was an intense eight-hour erection along with nausea and vomiting, an incident that hinted at the peptide’s unexpected sexual effects.

To commercialize the tanning angle, melanotan I was licensed to an Australian company that later became Clinuvel. Meanwhile, melanotan II was licensed to Palatin Technologies for sexual dysfunction research. Palatin eventually stopped developing melanotan II and focused on a related compound, bremelanotide, a slightly altered version of melanotan II.

Bremelanotide went through several rounds of clinical testing. An early nasal spray version was halted by the FDA in 2007 because it temporarily raised blood pressure. Researchers reformulated it as an injection and continued testing, eventually running successful Phase III trials for female sexual dysfunction. After several licensing deals and corporate shifts, bremelanotide was submitted to the FDA and officially approved in 2019 for treating low sexual desire in premenopausal women.

Mechanism of Action

PT-141 activates melanocortin receptors, specifically MC3R and MC4R, in the central nervous system. Unlike conventional treatments for sexual dysfunction, PT-141 targets brain pathways involved in sexual arousal and desire. It binds to these receptors, stimulating the release of neurotransmitters that enhance sexual motivation and response. This action occurs primarily in the hypothalamus and other brain regions, promoting increased libido and sexual function without directly affecting vascular systems. The peptide’s unique mechanism allows it to address conditions like HSDD and erectile dysfunction through neurological pathways, offering an alternative for patients who do not respond to traditional therapies.

Structure and Pharmacology

PT-141, or Bremelanotide, is a cyclic heptapeptide with the amino acid sequence Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-OH. Its molecular formula is C50H68N14O10, and it has a molecular weight of approximately 1025.2 g/mol. The peptide’s structure features a lactam bridge between aspartic acid and lysine, enhancing its stability and receptor-binding affinity. This design allows PT-141 to effectively target melanocortin receptors in the CNS.

Pharmacologically, PT-141 exhibits a distinct profile as a non-selective melanocortin receptor agonist. After administration, typically via subcutaneous injection, it is absorbed into the bloodstream and crosses the blood-brain barrier to exert its effects. The peptide’s half-life, while not precisely detailed in available data, is estimated to be in the range of several hours (typically 2-6 hours), supporting its use in clinical settings for sustained activity. PT-141 undergoes hepatic metabolism, with excretion primarily through renal pathways. Its pharmacokinetics enable rapid onset of action, often within hours, making it suitable for on-demand treatment of sexual dysfunction. The peptide’s ability to modulate neurological pathways without significant vascular effects distinguishes it from other therapeutic agents in its class.

Dosages

PT-141 is typically administered via subcutaneous injection for the treatment of sexual dysfunction, such as HSDD in premenopausal women. The standard dosage for adults, as approved for clinical use, is 0.5–1.75 mg injected approximately 45 minutes before anticipated sexual activity. Patients are advised not to exceed one dose within a 24-hour period and to limit use to no more than eight doses per month to minimize potential side effects. Dosage adjustments are not typically recommended, as the peptide’s efficacy and safety have been studied at this specific dose. For other potential uses, such as erectile dysfunction, dosing regimens remain under investigation, with clinical trials exploring similar subcutaneous administration protocols.

Warnings and Cautions

PT-141 requires careful consideration before use due to potential risks. People with uncontrolled high blood pressure, heart disease, or a history of cardiovascular events should avoid this medication, as it may increase blood pressure or cause adverse cardiac effects. Pregnant or breastfeeding women should not use PT-141, as its safety in these populations has not been established. The peptide may cause nausea, flushing, headache, or injection site reactions, which typically resolve but warrant monitoring. Patients with a history of skin conditions, particularly melanoma, should exercise caution due to the peptide’s melanocortin receptor activity, which could theoretically stimulate pigment-producing cells. Combining PT-141 with other medications affecting blood pressure or heart function may heighten risks, so medical consultation is a must.

Research & Clinical Trials

A Melanocortin Agonist for the Treatment of Sexual Dysfunction

This study concluded that bremelanotide (PT-141), a synthetic peptide that activates specific brain receptors (MC3R and MC4R), shows strong potential as a treatment for sexual dysfunction, particularly erectile dysfunction.

In animal models like rats and primates, PT-141 reliably caused penile erections. It also activated neurons in the hypothalamus, a brain area involved in sexual behavior, as shown by increased c-Fos activity (a marker of neuron activation). Additionally, the same brain regions were shown to be directly connected to the genitals.

In human trials, PT-141 caused a quick, dose-dependent increase in erectile activity, both in healthy men and in men with erectile dysfunction. The findings support PT-141 as a promising CNS-acting therapy for sexual performance issues, working through brain pathways rather than just affecting blood flow like traditional drugs (e.g., Viagra). [1]

PT-141 as a Treatment for Erectile Dysfunction

Even though there are several current treatments for erectile dysfunction (ED), like pills called PDE5 inhibitors, injections into the penis, vacuum pumps, and penile implants, many men either don’t respond to them or stop using them because of side effects, discomfort, or poor results. Because of this, researchers are now looking into new types of treatments that work in different ways.

One of the most promising new options is a peptide called bremelanotide (PT-141), which works on the brain and can trigger erections without the need for sexual arousal. It has shown good results even in men who don’t respond to current pills and appears to be safe. Other peptides being studied act more directly on the penis, including medications that improve blood flow or nerve signals, and may be useful for men whose current treatments don’t work due to problems with their body’s natural nitric oxide system.

Regenerative methods like stem cell therapy and low-intensity shock wave therapy are also being tested and have shown early promise, especially in men with ED caused by diabetes or surgery. Researchers are also working on easier and more effective ways to take these peptides, such as skin creams or pills that dissolve under the tongue. While these new treatments are still being studied, they offer hope for men with ED who haven’t had success with traditional options. [2]

Long-Term Safety and Efficacy of PT-141 for HSDD

The study found that bremelanotide (PT-141) is both an effective and well-tolerated long-term treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Over the course of the 52-week open-label extension of the RECONNECT trials, women who had previously completed the 24-week double-blind core phase and continued using PT-141 as needed experienced sustained improvements in sexual desire and reductions in emotional distress related to their low interest in sex. These improvements were measured using validated clinical tools such as the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS), showing continued benefit for women regardless of whether they initially received placebo or active treatment.

Importantly, no new safety issues emerged during the extended treatment period, reinforcing the favorable safety profile of PT-141. The most commonly reported side effects, nausea, flushing, and headache, were mostly mild to moderate in severity and consistent with previous phases of the study. The findings suggest that PT-141 acts centrally on the brain’s melanocortin system, which plays a key role in sexual motivation and arousal, allowing it to work independently of visual or physical sexual stimulation. This unique mechanism makes it especially valuable for women who may not respond to other treatment approaches, such as those targeting hormonal or peripheral pathways.

Overall, these results support PT-141 as a promising non-daily, on-demand option for women with HSDD, offering an alternative to daily oral medications like flibanserin. Its ability to produce a clinically meaningful response in desire and satisfaction, along with its ease of administration and manageable side effect profile, positions it as a significant advancement in the treatment of female sexual dysfunction. Ongoing and future studies may further establish its role in broader and more diverse patient populations, as well as explore potential benefits in combination with other therapeutic modalities. [3]